Treatment of erectile dysfunction (ED) in hypertensive subjects remains to be formally established. There is currently no standardized treatment for ED in hypertensive subjects. In this study, we tested our hypoth- 
Introduction
Penile erection is evoked by elevated pressure in the corpus cavernosum, resulting from the relaxation of the cavernous smooth muscles and its arterioles. The main relaxant substance has been determined to be nitric oxide (NO), which is liberated from neurons and endothelium in the corpus cavernosum (1) . Erectile dysfunction (ED) often occurs in the elderly and subjects with diabetes mellitus (2) . Hypertension has also been thought to be a risk factor for ED (2) . The pathogenesis of ED in the setting of hypertension has been reported to involve atherosclerotic vascular damage (3, 4) . Using spontaneously hypertensive rats (SHR), we recently demonstrated that neuronal NO-and carbon monoxide (CO)-dependent relaxation in the corpus cavernosum is impaired in ED in the setting of hypertension (5) . However, it remained unclear whether hypotensive drugs improve ED in the setting of hypertension. Some hypotensive drug classes, such as β-blockers, α1-blockers, α-methyldopa, angiotensin-converting enzyme (ACE) inhibitors and calcium antagonists, have been reported to induce ED in humans (6) . However, it has not been determined whether the impaired erectile function is induced as a side effect of the hypotensive drug or by hypertension per se. In particular, it remains unclear whether treatment with a hypotensive drug affects the neuronal system of the penile corpus cavernosum in the setting of hypertension. Calcium antagonists (7) and ACE inhibitors (8) have been shown to augment NO release from the endothelium of blood vessels. Some dihydropyridine calcium antagonists (9) and ACE inhibitors (10) have been shown to reduce oxidative stress in hypertensive patients. Therefore, it is possible that treatment with a hypotensive agent will improve ED in the setting of hypertension, as a result of improving endothelial function and/or augmenting NO in response to diminished oxidative stress.
In view of the above, we used SHR as a model of hypertension (5, 11) to elucidate whether hypotensive drugs improve the impaired relaxation of the corpus cavernosum in hypertension state, and if so, whether the neuronal or endothelial systems of the corpus cavernosum are involved in this improvement.
Methods
These experiments were approved by the Animal Research Committee of Saitama Medical School.
Animals and Hypotensive-Drug Treatments
We used 10-week-old male SHR/Izm as a model of hypertension (Funabashi Farms, Funabashi, Japan). The animals were housed in a temperature-controlled (24°C) facility under a 12-h on/12-h off light cycle. The animals had free access to laboratory rat chow and tap water. The rats were treated with tap water containing amlodipine besilate (5, 10 or 20 mg/kg body weight), imidapril hydrochloride (1, 5 or 10 mg/kg body weight) or hydralazine hydrochloride (2.5 mg/day) for 4 weeks from the age of 10 weeks.
Reagents
Amlodipine besilate (amlodipine) and imidapril hydrochloride (imidapril) were obtained from Sumitomo Pharmaceuticals Co., Ltd. (Tokyo, Japan) and Tanabe Seiyaku Co., Ltd. (Osaka, Japan), respectively. Hydralazine hydrochloride (hydralazine), guanethidine sulphate (guanethidine), atropine sulphate (atropine), phenylephrine hydrochloride (PhE), papaverine (PAP), tetrodotoxin (TTX), acetylcholine chlo-
(L-NNA) and zinc protoporphyrin-IX (ZnPP) were obtained from Sigma Chemical Co. (St. Louis, USA). Amlodipine, imidapril and hydralazine were dissolved in tap water for drinking. All other reagents were dissolved in distilled water.
Measurement of Blood Pressure
Systolic blood pressure (SBP) and heart rate in control rats and rats treated with each drug were measured without anesthesia by the tail-cuff method using a plethysmograph (PS-600; Riken Kaihatsu, Tokyo, Japan) before and weekly after the initiation of the treatment with each drug. 
Preparation
Rats were anesthetized with intraperitoneal injection of pentobarbital sodium (0.4 mg/kg) and sacrificed by bleeding from the carotid arteries. The penis was rapidly removed, the corpus cavernosum (approximately 3 × 12 mm) was set in a Magnus chamber filled with 10 ml Krebs solution, and isometric tension was measured as described previously (5) . The initial resting tension applied to each strip was adjusted to 2 g (12, 13) . At the end of the experiments, PAP (10 − 4 mol/l, final concentration) was added to the corpus cavernosum to attain the maximal relaxation, and the weight of each strip was measured after being removed from the organ bath.
Experimental Design

Measurements of Relaxation in Response to Electrical Field Stimuration
The corpus cavernosum obtained from rats with or without hypotensive treatment was equilibrated with Krebs solution containing guanethidine (5 × 10 − 6 mol/l, final concentration) and atropine (10 − 6 mol/l, final concentration) for 90 min to deplete endogenous norepinephrine and block cholinergic endothelial relaxation. After stimulating contraction through the addition of PhE (10 − 5 mol/l, final concentration) for 10 min, the strip was subjected to relaxation in response to electrical field stimulation (EFS) using 
Measurements of the Contraction Induced by Phenylephrine or Endothelium-Dependent or -Independent Relaxation
SHR were treated with amlodipine (10 mg/kg body weight, n= 10), imidapril (5 mg/kg body weight, n= 10) or hydralazine (2.5 mg/day, n= 10). After the corpus cavernosum strips were equilibrated with Krebs solution containing guanethidine and atropine for 90 min as described above, the contraction in response to PhE ( 
Nitrate/Nitrite Levels in the Corpus Cavernosum Stimulated by EFS
Levels of nitrate/nitrite (NOx) in the corpus cavernosum tissues obtained from amlodipine-treated SHR (10 mg/kg body weight, n= 8) and control SHR (n= 8) were measured after stimulation by EFS of 16 Hz using a Nitrate/Nitrite assay kit (Cat No. 780001; Cayman Chemical Co., Ann Arbor, USA). The concentration of NOx was normalized to the weight of a strip of the corpus cavernosum and expressed as nmol/mg weight.
Measurements of Guanosine 3´,5´-Monophosphate Levels
After stimulation by EFS of 16 Hz, the levels of guanosine 3′,5′-monophosphate (cGMP) in tissues obtained from amlodipine-treated (10 mg/kg body weight, n= 8) and control SHR (n= 8) were measured using a cGMP enzyme immunoassay system (Amersham Pharmacia Biotech Inc., Piscataway, USA).
Thiobarbituric Acid Reactive Substance Levels and Superoxide Dismutase Activity in the Serum or Corpus Cavernosum
Thiobarbituric acid reactive substance (TBARS) levels in the serum or corpus cavernosum obtained from amlodipinetreated (10 mg/kg body weight; n= 8) and control SHR (n= 8) were measured by the thiobarbituric acid assay method of Yagi as described previously (15) . Superoxide dismutase (SOD) activity in the serum or corpus cavernosum was measured by the modified assay method of Oyanagui as described previously (16) . The TBARS levels and SOD activity in the corpus cavernosum were normalized to the weight of the strip (unit: nmol/g wet tissue or U/g wet tissue).
Statistical Analysis
Results were expressed as the mean±SEM. Statistical analysis was performed using paired or unpaired two tail t-test or a one-way analysis of variance (ANOVA). When ANOVA was used and when this analysis indicated significance (at the 0.05 level), post-hoc test analysis (Fisher's protected least significant difference) was used to determine which conditions were significantly different from each other. Values of p< 0.05 were considered to indicate statistical significance.
Results
Effect of Hypotensive Drugs on SBP
Amlodipine (10 mg/kg body weight), imidapril (5 mg/kg body weight) and hydralazine (2.5 mg/day) achieved similar reductions in SBP after 4 week-drug treatment ( Table 1) .
Effect of TTX on EFS-Induced Relaxation in the Corpus Cavernosum of SHR
To clarify the mechanisms of the relaxation in response to EFS, TTX was added to organ bath, and the tissues were left to stand for 10 min. The relaxation in response to EFS was abolished by TTX (10 − 7 mol/l, final concentration; Fig. 2 ),
indicating that EFS-induced relaxation is a neuronal response in the corpus cavernosum.
Effect of Hypotensive Drugs on the Response to EFS in the Corpus Cavernosum
The EFS-induced relaxation response was examined in strips of the corpus cavernosum treated with each hypotensive drug (amlodipine, imidapril or hydralazine). Treatment with amlodipine and imidapril improved the impaired relaxation of SHR in response to EFS from 2 Hz to 64 Hz and from 4 Hz to 16 Hz (Fig. 3A , p< 0.05 or p< 0.01, n= 20), respectively, while hydralazine did not affect the relaxation in response to EFS (Fig. 3A, p> 0.5, n= 20) . The relaxation in response to EFS increased in a dose-dependent manner ( Fig. 3B-a ; n= 10 each), and in an SBP-dependent manner ( Fig. 3C ; n= 10 each, correlation coefficient= −0.41, p< 0.01) in the amlodipinetreated SHR, but not in imidapril-treated SHR (Fig. 3B-b and C; n= 10 each, correlation coefficient= −0.25).
Effect of Hypotensive Drugs on the Relaxation Caused by NO or CO Derived from the Nerve in the Corpus Cavernosum
The corpus cavernosum in SHR treated with hypotensive drugs was preincubated with L-NNA to block NO synthesis or with L-NNA and ZnPP to block NO and CO synthesis. The relaxation in response to EFS was then examined. NO-dependent relaxation in response to EFS from 2 Hz to 64 Hz or from 4A ; p< 0.05 or p< 0.01, n= 20 each), respectively. NO-dependent relaxation in response to EFS of 64 Hz was decreased by hydralazine ( Fig. 4A ; p< 0.05, n= 20 each). CO-dependent relaxation in response to EFS from 4 Hz to 64 Hz was increased by hydralazine ( Fig. 4B ; p< 0.05 or p< 0.01, n= 10 each), and was not affected by amlodipine or imidapril.
Effect of Amlodipine on NOx and cGMP Levels in the Corpus Cavernosum
To examine the mechanisms of the improvement of neuronal NO synthesis in the corpus cavernosum of SHR treated with amlodipine, NOx and cGMP levels in the corpus cavernosum were measured. Treatment with amlodipine did not affect the basal level of NOx in the corpus cavernosum, and the level of NOx in the corpus cavernosum was increased by EFS of 16 Hz, as compared with the basal level ( Table 2 , p< 0.05). The NOx and cGMP levels in the corpus cavernosum of the amlo- 
Fig. 4. Effect of hypotensive drugs on relaxation induced by neuronal NO or CO in the corpus cavernosum of SHR. NO-and CO-dependent relaxation in response to
Effect of Amlodipine on TBARS Levels and SOD Activity in the Corpus Cavernosum and Serum
To examine mechanisms of the augmentation of the neuronal NO concentration in the corpus cavernosum, we also measured levels of TBARS and SOD activity in the corpus cavernosum and serum. Levels of TBARS in the corpus cavernosum and serum were similar between control SHR and amlodipine-treated SHR (Table 3 ; p> 0.05). SOD activity in the corpus cavernosum of the amlodipine-treated SHR was less than that of the control SHR (Table 2 ; p< 0.01), but not less than the activity in the serum (Table 3 ; p> 0.05).
Effect of Hypotensive Drugs on Relaxation in Response to ACh and SNP in the Corpus Cavernosum
The role of vascular factors in relaxation in response to each hypotensive drug (amlodipine 10 mg/kg body weight, imidapril 5 mg/kg body weight or hydralazine 2.5 mg/day) was examined in the corpus cavernosum strips of SHR. Amlo- (Fig. 5A, p< 0.05) . Relaxation of the corpus cavernosum in SHR in response to SNP was slightly increased only by the treatment with amlodipine ( Fig. 5B ; p< 0.05).
Fig. 5. Effect of hypotensive drugs on endothelium-dependent or -independent relaxation in the corpus
Effect of Hypotensive Drugs on PhE-Induced Contraction
Contraction in response to PhE was similarly inhibited by the treatment with each hypotensive drug, as compared with nontreated SHR ( Fig. 6 ; p< 0.05, n= 10 each).
Discussion
Penile erection is impaired not only in the elderly and diabetics, but also in hypertensives (2) . It was recently demonstrated that impaired relaxation in the corpus cavernosum of SHR might result from an impaired neuronal NO-and COdependent relaxation in the corpus cavernosum (5, 17) . In the present study, we examined the effect of treatment with hypotensive agents on impaired relaxation in the corpus cavernosum of SHR. EFS-induced relaxation and NO-dependent relaxation in the corpus cavernosum of SHR, which were measured under circumstances that excluded the possibility of ACh-induced NO release from the endothelium by atropine, was increased by amlodipine or imidapril. Further, the relaxation in response to EFS was abolished by treatment with TTX. These results indicate that neurogenic relaxation in the corpus cavernosum is improved by treatment with amlodipine or imidapril. This improvement in the relaxation results from augmented neuronal NO synthesis and/or release in the corpus cavernosum, because NO-dependent relaxation was increased by the treatment with amlodipine and imidapril, as compared with the level in control SHR. After treating with imidapril, relaxation in response to EFS was increased in a dose-dependent manner, but in an SBP-independent manner. Therefore, the improvement in neurogenic relaxation may result from a specific action of imidapril, rather than from the effect of imidapril on blood pressure. Neurogenic relaxation of the corpus cavernosum was improved in a dose-dependent manner and in an SBP-dependent manner by the treatment with amlodipine. Furthermore, the relaxation was much greater in the amlodipine-treated SHR than in the imidapril-treated SHR, although the blood pressure was lowered to the same level by both treatments. Therefore, this improvement in neurogenic relaxation may result not only from a blood pressure-lowering effect, but also from the specific action of amlodipine. On the other hand, hydralazine did not change the relaxation in response to EFS, but did inhibit NO-dependent relaxation in response to EFS of 64 Hz. Therefore, treatment with hydralazine may suppress the neuronal NO system in the corpus cavernosum. It has been reported that neuronal relaxing factors exhibit different properties at different frequencies of EFS (5) . Thus it is possible that any of the individual components of penile erection of the rat are inhibited by hydralazine via an impairment of NO-induced relaxation. We also examined the effect of treatment with hypotensive agents on another neuronal relaxing system, the CO-related system, in the corpus cavernosum of SHR. CO-dependent relaxation in the corpus cavernosum of SHR was increased by hydralazine. This result may be partially due to the hydralazine-induced suppression of NOdependent relaxation in the tissues. And this action of hydralazine may be specific, because neither amlodipine nor imidapril affected the CO-dependent relaxation in the tissues.
To clarify the specific action of amlodipine on EFSinduced relaxation in SHR, we examined the mechanisms of the improvement of neuronal NO synthesis and/or release in the corpus cavernosum by amlodipine. We found that amlodipine did not affect the base level of NOx, which was increased by EFS. The increased NOx level and cGMP level in the corpus cavernosum were greater in amlodipine-treated SHR than in control SHR. These results suggest that amlodipine improves neurogenic relaxation of the corpus cavernosum in SHR through augmented neuronal NO synthesis and/ or release. In addition, increased relaxation of the corpus cavernosum muscle may have played some role in the augmentation of the NO-induced activation of soluble guanylate cyclase, because the relaxation of the corpus cavernosum in response to SNP was slightly increased by the treatment with amlodipine. It is well known that hypertensive patients have increased oxidative stress levels and that increased oxidants trap NO, resulting in an impairment of the endothelial function of blood vessels (10) . In our previous study, we demonstrated that increased oxidative stress in SHR suppressed the bioavailability of NO, resulting in ED through a reduction of the relaxation induced by NO from neurons in the corpus cavernosum of SHR (5) . Therefore, antioxidant therapy may improve the relaxing function in the corpus cavernosum of SHR. We examined the effect of amlodipine on oxidative stress using TBARS and SOD activity as markers, because dihydropyridine calcium channel blockers, such as amlodipine, have been reported to suppress oxidative stress in hypertensive patients (9) . In the present study, TBARS levels in serum and tissue were not decreased by the treatment with amlodipine, while SOD activity in the tissue was suppressed, suggesting that the amlodipine-induced improvement of the relaxation in the corpus cavernosum may not be attributable to an amlodipine-induced decrease in oxidative stress. This result conflicts with our previous result. Thus the improvement of the relaxation in the corpus cavernosum by amlodipine may not be due to a specific action in SHR. Recently, it was reported that the level of asymmetrical dimethyl arginine (ADMA), as an endogenous NOS inhibitor, was increased in hypertensive subjects (18) . It is necessary to examine whether amlodipine inhibits ADMA in the corpus cavernosum of SHR. Okamura et al. reported that addition of amlodipine to the medium of an organ bath impaired the relaxation in the corpus cavernosum of canines in response to EFS (19) .
Although the exact reason for this discrepancy is not yet known, it might be due to differences in the species and treatment periods. In fact, there are also conflicting reports in humans, with one study showing that amlodipine did not affect sexual function (20) , and another reporting that the drug increased sexual symptom distress (21) .
In the present study, we examined endothelial function in the corpus cavernosum of hypotensive drug-treated SHR, because ACE inhibitors (8) and calcium antagonists have been reported to improve endothelial function through an enhanced action of NO released from the endothelium of blood vessels in dogs and hypertensive humans (7, 22, 23) . We demonstrated that the relaxation of corpus cavernosum tissue in response to ACh was suppressed by treatment with imidapril or hydrazine, and was not affected by treatment with amlodipine. These results indicate that the improvement of the relaxation in response to EFS in the amlodipine-and imidapril-treated SHR does not result from a change of endothelial function in the corpus cavernosum, even though the tissues were not atropinized.
We demonstrated that the contraction in response to PhE was similarly impaired by 4-week treatment with either amlodipine, imidapril or hydralazine. The noradrenergic neuron system of the corpus cavernosum is thought to control the detumescence of penile erection (24) . Therefore, long-term treatment with hypotensive drugs may inhibit α1-adrenoceptor function of the corpus cavernosum, thereby inhibiting the detumescence of erection. Thus, treating hypertension with the drugs used in the present study might be beneficial for ED through the inhibition of detumescence of erection by mechanisms other than enhancement of NO synthesis and/or release.
In summary, impaired relaxation in the corpus cavernosum of SHR was improved by the treatment with amlodipine or imidapril in the present study. The mechanisms of this improvement by amlodipine or imidapril were related to an augmented neuronal NO synthesis and/or release, but not to improved endothelial function. Hydralazine improved the function of the neuronal CO system, suppressed the NO system and did not affect relaxation in the corpus cavernosum of SHR. We conclude that amlodipine and imidapril may be helpful in treating the ED associated with hypertension.
